Overview

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Status:
RECRUITING

Trial end date:
2032-12-01

Target enrollment:

Participant gender:

Summary

A Randomised, Double-blind, Multicenter Phase Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype

Phase:

PHASE3

Details

Lead Sponsor:

Chipscreen Biosciences, Ltd.

Treatments:

Cyclophosphamide
Doxorubicin
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
Prednisone
Vincristine